Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Vojinov, Sasa; Levakov, Ivan; Jeremic, D.; Zivojinov, S.; Marusic, G.

doi:10.2298/vsp1104321v

Cited by 4 publications

(3 citation statements)

References 24 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such observations may have clinical implications in cases where tumor cells showed expression of these receptors, potentially responsive to estrogen and survive in conditions of androgen deprivation and also for treatment with estrogen antagonists 24,25 .…”

Section: Discussionmentioning

confidence: 95%

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This can also be achieved by surgical or pharmacological castration. Administration of gonadotropin-releasing hormone (LH-RH) agonists and/or antiandrogen leads to a pharmacological blockade 7 .…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia

et al. 2020

View full text Add to dashboard Cite

Background/Aim. Prostate carcinoma (PCa) and its parent organ are influenced by hormones, which is used for therapeutic purposes. Through androgen receptors (AR) androgens influence cell growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity of the prostate, as well as development and progression of PCa. An antiandrogen therapy is carried out in patients with metastatic PCa, in order to block effects of androgens. By conducting immunohistochemical analysis of androgen receptors in the PCa tissue, we can assume how the tumour will react to an administered antiandrogen therapy, both in androgen-positive and androgen-negative, resistant tumours. Knowledge of the presence of AR in the tumour tissue may serve as a prognostic indicator in histopathological analysis. The aim of this study was to evaluate the expression of AR in patients with benign prostatic hyperplasia (BPH) and in those with PCa, before

show abstract

“…This can be achieved by surgical or pharmacological castration. Administration of luteinizinghormone-releasing hormone (LHRH) agonists and/ or anti-androgen leads to a pharmacological block- [11,12]. Using immunohistochemical determination of ARs in patients with PCa, we wished to substantiate the claims that the majority of tumors are androgendependent from the beginning, and that the initial anti-androgen therapy is useful.…”

Section: Introductionmentioning

confidence: 99%

Stereological analysis of androgen receptors in prostate cancer and benign prostatic hyperplasia

Trivunic-Dajko

Bogdanovic²,

Vojinov³

et al. 2018

Med pregl

Self Cite

View full text Add to dashboard Cite

Introduction. Through androgen receptors, androgens regulate prostate cellular growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity, as well as development and progression of prostate cancer. Prostate cancer, and its primary glandular tissue are influenced by hormones, and it is used for therapeutic purposes. Anti-androgen treatment is carried out in patients with metastatic prostatic cancer, in order to block effects of androgens. Immunohistochemical analysis of androgen receptors in the prostate cancer tissue may help us to assume how the tumors will react to the anti-androgen therapy, if they are androgen-positive,-negative, or hormone resistant tumors. Knowledge of the presence of androgen receptors in the tumor tissue may be a prognostic indicator in histopathological analysis. The aim of this study was stereological evaluation of androgen receptor expression in patients with benign prostatic hyperplasia and in patients with prostatic cancer, before therapy. Material and Methods. Immunohistochemical analysis was carried out using anti-human androgen receptor monoclonal antibody 441. The presence and intensity of the androgen receptors were evaluated in 195 patients: 165 with benign prostatic hyperplasia and 30 with prostatic cancer using Weibel's multipurpose M 42 stereological test system. Material was obtained by needle biopsy or transurethral resection of the prostate. Results. All secretory cells in patients with benign prostatic hyperplasia were androgen positive, while in patients with prostatic cancer, all tumors were mostly androgen positive, some with foci of negativity. The resulting negative correlation with Gleason score and International Society of Urological Pathology grade was not statistically significant. Conclusion. Study results of stereological analysis of androgen receptors indicate that prior the therapy prostate cancer is androgendependent, with a high level of androgen receptor expression, although slightly lower compared to benign prostatic hyperplasia.

show abstract

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade

Cited by 4 publications

References 24 publications

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia

Stereological analysis of androgen receptors in prostate cancer and benign prostatic hyperplasia

Contact Info

Product

Resources

About